drugset / Trial / NCT06132178
Psilocybin rTMS for Treatment Resistant Depression
RandomizedFactorialTriple-blindTreatment
Summary
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
Timeline
- Start
- 2025-01-10
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 1 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |